Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034100965> ?p ?o ?g. }
- W2034100965 endingPage "271" @default.
- W2034100965 startingPage "265" @default.
- W2034100965 abstract "Objective. To investigate adenocarcinoma of the prostate in a single population with an extended follow-up period. Material and methods. Using the Icelandic Cancer Registry, we identified all Icelandic men diagnosed with prostate cancer between 1983 and 1987. Disease stage, initial treatment and follow-up information were obtained from hospital records and death certificates. A critical evaluation was made of the accuracy of the death certificates regarding prostate cancer. All available histology information was reviewed and graded according to the Gleason grading system. Results. A total of 414 men were diagnosed with adenocarcinoma of the prostate. Of these, 370 were alive at the time of diagnosis and stage could be determined. Four stage groups were defined: focal incidental (n=50); localized (n=164); local advanced (n=32); and metastatic disease (n=124). The mean age at diagnosis was 74.4 years (range 53–94 years). The combined Gleason score was 2–5 in 89, 6–7 in 117, 8–10 in 117 and unknown in 47 cases. The median follow-up period for the group was 6.15 years (range 0.3–19.8 years). Thirty men received treatment with curative intent: radiation therapy, n=20; and radical prostatectomy, n=10. A total of 334 patients died during the follow-up period, of whom 168 (50%) died of prostate cancer. Prostate cancer-specific survival at 10 and 15 years was 100% and 90.6%, respectively for focal incidental cancer; 73.1% and 60.8% for men with localized disease; 23.4% and 11.7% for local advanced disease; and 6.81% and 5.45% for metastatic disease. A Cox multivariate analysis showed age, stage and Gleason score to be independent predictors of prostate cancer death. A total of 104 patients with localized disease and a Gleason score of ≤7 received deferred treatment. The cause-specific survival for this group was 95.6%, 86.5% and 79.2% at 5, 10 and 15 years, respectively. Death certificates were judged to be accurate with regard to prostate cancer in nearly all instances (96%). Conclusions. During an extended follow-up period, half of all patients with prostate cancer died from the disease. Males with localized disease and a favorable tumor grade fared well with deferred treatment. However, a higher stage and grade were associated with substantial prostate cancer mortality. Death certificates were accurate as far as prostate cancer was concerned." @default.
- W2034100965 created "2016-06-24" @default.
- W2034100965 creator A5004019119 @default.
- W2034100965 creator A5014267065 @default.
- W2034100965 creator A5024846870 @default.
- W2034100965 creator A5041663976 @default.
- W2034100965 creator A5044911218 @default.
- W2034100965 creator A5057209063 @default.
- W2034100965 creator A5068342767 @default.
- W2034100965 creator A5086006915 @default.
- W2034100965 creator A5090411799 @default.
- W2034100965 date "2006-01-01" @default.
- W2034100965 modified "2023-10-18" @default.
- W2034100965 title "Adenocarcinoma of the prostate in Iceland: A population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987" @default.
- W2034100965 cites W1482275429 @default.
- W2034100965 cites W186194822 @default.
- W2034100965 cites W1919183147 @default.
- W2034100965 cites W1966159820 @default.
- W2034100965 cites W1986526265 @default.
- W2034100965 cites W1988696103 @default.
- W2034100965 cites W1999781922 @default.
- W2034100965 cites W2002869467 @default.
- W2034100965 cites W2006115709 @default.
- W2034100965 cites W2021726481 @default.
- W2034100965 cites W2023283153 @default.
- W2034100965 cites W2025889116 @default.
- W2034100965 cites W2025990348 @default.
- W2034100965 cites W2086428130 @default.
- W2034100965 cites W2099497643 @default.
- W2034100965 cites W2103086081 @default.
- W2034100965 cites W2165983722 @default.
- W2034100965 cites W2417983633 @default.
- W2034100965 cites W2465802396 @default.
- W2034100965 cites W2470378909 @default.
- W2034100965 cites W4233182856 @default.
- W2034100965 cites W4245762929 @default.
- W2034100965 doi "https://doi.org/10.1080/00365590600750110" @default.
- W2034100965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16916765" @default.
- W2034100965 hasPublicationYear "2006" @default.
- W2034100965 type Work @default.
- W2034100965 sameAs 2034100965 @default.
- W2034100965 citedByCount "22" @default.
- W2034100965 countsByYear W20341009652012 @default.
- W2034100965 countsByYear W20341009652013 @default.
- W2034100965 countsByYear W20341009652015 @default.
- W2034100965 countsByYear W20341009652017 @default.
- W2034100965 countsByYear W20341009652018 @default.
- W2034100965 countsByYear W20341009652019 @default.
- W2034100965 countsByYear W20341009652021 @default.
- W2034100965 crossrefType "journal-article" @default.
- W2034100965 hasAuthorship W2034100965A5004019119 @default.
- W2034100965 hasAuthorship W2034100965A5014267065 @default.
- W2034100965 hasAuthorship W2034100965A5024846870 @default.
- W2034100965 hasAuthorship W2034100965A5041663976 @default.
- W2034100965 hasAuthorship W2034100965A5044911218 @default.
- W2034100965 hasAuthorship W2034100965A5057209063 @default.
- W2034100965 hasAuthorship W2034100965A5068342767 @default.
- W2034100965 hasAuthorship W2034100965A5086006915 @default.
- W2034100965 hasAuthorship W2034100965A5090411799 @default.
- W2034100965 hasConcept C121608353 @default.
- W2034100965 hasConcept C126322002 @default.
- W2034100965 hasConcept C126894567 @default.
- W2034100965 hasConcept C127413603 @default.
- W2034100965 hasConcept C143998085 @default.
- W2034100965 hasConcept C146357865 @default.
- W2034100965 hasConcept C147176958 @default.
- W2034100965 hasConcept C151730666 @default.
- W2034100965 hasConcept C2776235491 @default.
- W2034100965 hasConcept C2777286243 @default.
- W2034100965 hasConcept C2778527826 @default.
- W2034100965 hasConcept C2779466945 @default.
- W2034100965 hasConcept C2780192828 @default.
- W2034100965 hasConcept C2780558122 @default.
- W2034100965 hasConcept C2781182431 @default.
- W2034100965 hasConcept C2908647359 @default.
- W2034100965 hasConcept C29456083 @default.
- W2034100965 hasConcept C71924100 @default.
- W2034100965 hasConcept C86803240 @default.
- W2034100965 hasConcept C99454951 @default.
- W2034100965 hasConceptScore W2034100965C121608353 @default.
- W2034100965 hasConceptScore W2034100965C126322002 @default.
- W2034100965 hasConceptScore W2034100965C126894567 @default.
- W2034100965 hasConceptScore W2034100965C127413603 @default.
- W2034100965 hasConceptScore W2034100965C143998085 @default.
- W2034100965 hasConceptScore W2034100965C146357865 @default.
- W2034100965 hasConceptScore W2034100965C147176958 @default.
- W2034100965 hasConceptScore W2034100965C151730666 @default.
- W2034100965 hasConceptScore W2034100965C2776235491 @default.
- W2034100965 hasConceptScore W2034100965C2777286243 @default.
- W2034100965 hasConceptScore W2034100965C2778527826 @default.
- W2034100965 hasConceptScore W2034100965C2779466945 @default.
- W2034100965 hasConceptScore W2034100965C2780192828 @default.
- W2034100965 hasConceptScore W2034100965C2780558122 @default.
- W2034100965 hasConceptScore W2034100965C2781182431 @default.
- W2034100965 hasConceptScore W2034100965C2908647359 @default.
- W2034100965 hasConceptScore W2034100965C29456083 @default.
- W2034100965 hasConceptScore W2034100965C71924100 @default.
- W2034100965 hasConceptScore W2034100965C86803240 @default.